Clinical Oncology - 2016;3(04)

Clinical Oncology

DECEMBER 10, 2016

[Foreword]

A szerkesztők

HUN 2016;3(04)

Clinical Oncology

DECEMBER 10, 2016

[Reminiscences of a Peer – Remembering Sándor Eckhardt]

KERPEL-FRONIUS Sándor

HUN 2016;3(04)

Clinical Oncology

DECEMBER 10, 2016

[News from the World]

HUN 2016;3(04)

Clinical Oncology

DECEMBER 10, 2016

[Side-effects of immunotherapy]

LANDHERR László

[The immune system has an important role in controlling and eradicating cancer cells. Antibody therapy against several negative immunologic regulators (checkpoints) has demonstrated promise in a variety of malignancies. The immune checkpoint blockade with antibodies against cytotoxic T lymphocyte- associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) and its ligand have a unique and distinct pattern of adverse events. Immune-related adverse events are most... tovább »

HUN 2016;3(04)

Clinical Oncology

DECEMBER 10, 2016

[Chemotherapy of multiple myeloma]

MIKALA Gábor, CEGLÉDI Andrea, CSACSOVSZKI Ottó, SZEMLAKY Zsuzsanna, PETŐ Mónika

[Multiple myeloma is a multifaceted haematological disease, a plasma cell malignancy that may pose an oncological differential diagnostic challenge. The importance of this disease is emphasized by its incidence. Since there are multiple novel therapies available for myeloma patients, decade-long survival in not uncommon; therefore, myeloma patients provide a signifi cant part of the patients referred to hematological clinics. In this review, fi rst the novel diagnostic criteria are introduced,... tovább »

HUN 2016;3(04)

Clinical Oncology

DECEMBER 10, 2016

[Long-term central venous access devices in oncology]

PAJKOS Gábor

[Long-term central venous access devices are essential in the management of oncology patients, as they minimize the discomfort caused by frequent venipuncture and cannulation. Indications of application of central venous accesses, possibilities of implantations, immediate and long term complications, they prevention and obviation has been reported based on guidelines and relevant publications. Long term implantable central venous accesses handled by well-trained and exercised team, working with... tovább »

HUN 2016;3(04)

Clinical Oncology

DECEMBER 10, 2016

[Individualized treatment of advanced/metastatic adult soft tissue sarcomas]

SZŰCS Zoltan, JONES L. Robin

[Considering the extreme histological heterogeneity of soft tissue sarcomas (STS), their management is an art of its own. Over the last decade the treatment of STSs has been slowly shifting towards a more individualized, histology driven tailored approach. With the availability of novel antineoplastic agents and the differential sensitivity of different subtypes of sarcomas to these drugs, we aim to provide some guidance in terms of optimal sequencing of therapies. Furthermore, we discuss some... tovább »

HUN 2016;3(04)

Clinical Oncology

DECEMBER 10, 2016

[Defi ciency of DNA-repair]

KOPPER László

[The cell uses the DNA to keep those information, which are vital to function properly. It is essential to maintain the integrity of the DNA, the stability of the genome. Since DNA damages, caused by external or internal factors, are continuously produced, DNA-repair mechanisms should be ready to identify and eliminate the damages. Either the repair system is successful and the cell can continue its duty, or, if the damages are unrepaired, the programed cell death (apoptosis) is activated... tovább »

HUN 2016;3(04)

Clinical Oncology

DECEMBER 10, 2016

[Treatment of anemia in cancer patients]

NAGYKÁLNAI Tamás

[Anemia in cancer can be resulted by the underlying malignant disease or related to the chemotherapy. Cancer-related anemia adversely effects quality of life and is associated with reduced survival. Clinical studies demonstrate that blood transfusions, ESAs, and correction of iron defi ciency are therapeutic options for anemic cancer patients.]

HUN 2016;3(04)

Clinical Oncology

DECEMBER 10, 2016

[Biopharmaceuticals]

LÉVAY György

[Biopharmaceuticals represent a new class of very effective medications in the management of debilitating and often life-threatening diseases but the costs of these therapies exceed the costs of regular therapies. Biological medicinal products (i.e. smaller proteins or monoclonal antibodies) are mostly complex macromolecules, produced by microbial or mammalian cell cultures in bioreactors through application of complex process technologies. After patent expiry, the production of compounds with... tovább »

HUN 2016;3(04)